Development and validation of a HPLC analytical assay method for efavirenz tablets: a medicine for HIV infections
DOI:
https://doi.org/10.1590/S1984-82502011000100012Keywords:
Efavirenz^i1^stablet as, High performance liquid chromatography^i1^squantitative analyAbstract
Efavirenz is a reverse transcriptase non analog nucleoside inhibitor used to treat HIV infections. A simple assay method by high performance liquid chromatography was developed and validated for efavirenz tablets. The physical chemical characteristics of efavirenz were investigated to developing the method. The method was validated observing the parameters described in USP 29. Analyses were performed by an ultraviolet detector at a 252 nm wavelength, on a reverse-phase column (C18, 250 mm x 3.9 mm, 10 μm), using an isocratic mobile phase containing acetonitrile/water/orthophosphoric acid (70:30:0.1). The validation parameters used were: selectivity, linearity, precision, accuracy, robustness, detection and quantification limits, and all resulting data were treated by a statistical method. The results obtained confirmed an alternative assay method for efavirenz tablets adequate for routine industrial use.Downloads
Download data is not yet available.
Downloads
Published
2011-03-01
Issue
Section
Articles
License
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
How to Cite
Development and validation of a HPLC analytical assay method for efavirenz tablets: a medicine for HIV infections . (2011). Brazilian Journal of Pharmaceutical Sciences, 47(1), 97-102. https://doi.org/10.1590/S1984-82502011000100012